Chronic Myeloid Leukemia Faceoff: UT Southwestern vs Mayo Clinic

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.

Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.